Lung cancer is currently the most lethal of malignant conditions in the Western world and is predicted to remain so for the foreseeable future (De Leij et al., 1987) . Of the five major groups of lung cancer, only small cell cancer (SCC) is observed to be highly chemo-and radiosensitive and yet the prognosis for patients with SCC remains very poor. Approximately 60% of SCC patients have metastases at the time of first presentation, restricting the use of surgery or radiotherapy and causing a strong reliance on the use of chemotherapy. The poor prognosis for SCC relates not only to its early and extensive metastasis but to its high rate of growth and the post-treatment emergence of chemoresistance (De Leij et al., 1987) . This invasive nature indicates the need to develop new agents with systemic efficacy against SCC.
The use of monoclonal antibodies (MAbs) for diagnosis (Cuttitta et al., 1984) , imaging (Mach et al., 1981; Smedley et al., 1983 ) and now therapy (Lobuglio et al., 1986; Epenetos et al., 1987) of malignant disease is an increasingly realistic objective. MAbs generated against surface antigens of SCC can be divided according to the nature and expression of their target antigens into five main clusters, as defined at the International Workshop on SCC, London 1987 (Souhami et al., 1988) . We have produced a panel of antibodies belonging to clusters w4 and 5, some of which have been previously described Waibel et al., 1987 Waibel et al., , 1988 . This paper describes the antibody SWAI1, which appears to belong to cluster w4 and which has been selected for in vivo evaluation because of its strong reactivity with both classic and variant SCC lines in vitro. This antibody is characterised by a very high capacity for in vivo localisation, relatively low retention in non-target organs and persistence at the target tumour. These characteristics suggest SWAl 1 to be a suitable candidate for use in the establishment of an in vivo model for the radioimmunotherapy of SCC tumours and in the long-term for use in clinical studies on imaging and therapy. The therapeutic application of such reagents as vehicles for the selective delivery of cytotoxins, or isotopes for imaging or therapy of SCC, is desirable in view of the present poor prognosis for patients with this disease (De Vita et al., 1985; Carney, 1987 grown in RPMI medium supplemented with 1 mM glutamine and 10% fetal calf serum. Cell line CORL47 was obtained from Dr P. Twentyman, MRC, Hills Road, Cambridge, England. The other cell lines employed for screening of antibody reactivity were generated in our own laboratory, or obtained from ATCC or from sources that have already been described (Stahel et al., 1986 ).
Monoclonal antibodies
Our procedure for antibody generation has been previously described (Stahel et al., 1985b at saturating concentration to the plate with SWAl 1 acting as positive control and SWA20 (Workshop cluster 5A) as negative control. Incubation was performed for 1 h at 37°C and then the plates were washed four times with PBS and 1% BSA. Radiolabelled SWAl 1 was then added (at a concentration giving one-half maximal binding in the absence of competition) and further incubation performed at 37°C for one hour. After final washing (x 4) individual wells were cut out and counted in a gamma counter.
Antibody labelling techniques lodogen 0.1mg (Pierce) was dissolved in 0.2ml chloroform and added to a 1 ml vial. The solvent was evaporated with a gentle stream of nitrogen and then 0.5mg of antibody in 0.25ml PBS was added. 1311 or 1251 (0.3mCi in 0.03ml) was added and the reaction continued for 15 min at 10°C with stirring. The reaction mixture was applied to a prepacked Sephadex G50 column which had been equilibrated with PBS (0.05 M phosphate buffer, 0.1 M sodium chloride). The solution was sterilised by passage through a 0.22,im filter (Millex GV). Human serum albumin 0.04 ml (25%) was added as a protein carrier and then radiochemical purity was assessed by thin layer chromatography using CEL300 polygram (Marchery Nagel) and methanol (85%). Radiochemical purity was generally in excess of 95%.
In vitro immunoreactivity
To determine the biological activity of radiolabelled SWAl 1, SW2 cells were washed three times in PBS (with 5% non-fat milk, 0.05% azide) and varying cell numbers were then incubated for 2 h at 4°C with a fixed amount of radiolabelled antibody (690,000 c.p.m.), After washing the activity in the cell pellet was counted. The number of counts remaining unbound was plotted against the reciprocal of the cell number so that the intercept on the y-axis indicates the theoretical unreactive fraction. The difference between the input and the estimated unreactive fraction (both in c.p.m.) represents the biological activity of the radiolabelled antibody (Trucco & de Petris, 1981) .
Determination of n and Ka
The number of antigenic sites, n, on the surface of SW2 cells capable of interaction with SWAl 1 and the association constant, K,, were also assessed as described by Trucco & de Petris (1981) . SW2 cells were washed three times in PBS (with 5% non-fat milk, 0.05% azide) and then dispensed at 5 x 104 cells per tube. A serial two-fold dilution of radiolabelled SWAIl was performed and 100p1 added to each tube. The total reaction volume was 0.5ml. The incubation was carried out at 4°C for 2 h and then the cells were washed five times as above. The data obtained were manipulated to allow a plot of r against rA -X to be made (where r is the number of antibody molecules bound per cell and A -X is the free antibody expressed as c.p.m.). The interactions of SWAl 1 with the leukaemic cell line K562 and human peripheral blood buffy coat were also evaluated using the same technique in an attempt to estimate the significance of heterogenous staining of buffy coat and bone marrow observed by an indirect immunofluorescence test. The SW2 xenograft model Female NMRI nu/nu mice were bred within the Biologisches Zentrallabor, Universitaetsspital, Zurich. Pathogen-free food and acidified drinking water were given ad libitum. Xenograft passage was performed by subcutaneous transplantation of 2-3mm3 pieces of SW2 tumour into 4-6-week-old animals. Within approximately three weeks tumours were ready for use in antibody localisation studies, having reached a size of approximately 1 cm3.
In vivo localisation studies
The in vivo distribution of SWA 11 was determined by simultaneous i.v. injection of 20 pg (10,uCi) of 131I-labelled SWAl 1 and the same amount and activity of a 125I-labelled anti-CEA. Both antibodies were of the IgG2a subclass. Thyroid blocking was achieved by the administration of two or three drops of Lugol's solution per 100ml of drinking water. Mice were dissected at days 2, 3, 4 and 7 and the various organs rinsed in PBS, weighed and counted in a two channel gamma counter. Localisation of antibody was expressed in absolute terms as the percentage of injected dose per gram of tissue (%IDg 1) and in relative terms as a tissue to blood ratio.
Gamma scintigraphy Tumour bearing mice were injected intravenously with 100pCi of 131I-labelled SWAI1 (100,uCi per 100,ug) and then imaged on days 2 and 4 using a pinhole collimator positioned 9cm from the target animal and linked to a Picker Dyna Camera 4. Images were generated from 50,000 counts acquired using an energy window of 25% centred on 364keV. No background subtraction technique was required. Animals were anaesthetised during imaging by intraperitoneal injection of 0.5 ml Nembutal (1:10 dilution in PBS). No thyroid blocking was employed in external scintigraphy studies.
Results

Antibody characterisation
Our results suggest that the antibody SWAI1 recognises the small cell carcinoma antigen cluster w4, which was previously defined by the antibodies SWA21 and SWA22, also established in our laboratory . The reactivity of these antibodies with cell lines is summarised in Table I . By indirect immunofluorescence SWA 11 was seen to react with all nine small cell carcinoma cell lines examined. With other lung derived lines reactivity was seen in one of four lines of adenocarcinoma origin, one of three squamous, none of two large cell and none of two mesothelial. Reactivity was also seen with one of three leukaemic cell lines. A clear homology was observed between all three antibodies in terms of pattern of cell line reactivity.
Antibody SWAI1 was unreactive with primary cultures of normal bronchial epithelial cells but against normal human peripheral blood buffy coat and bone marrow heterogenous staining was seen and FACS analysis on the buffy coat has indicated this to be due to cross-reactivity with 5% of the total white cell population. This reactivity is confined to about 40% of mature granulocytes. By agglutination assay no reactivity of SWAl1 was detected against cells bearing the red blood cell Ap, A2 B, 0, Rh-hr, Kell, Duffy, Kidd, X linked, Lewis, MNS or P antigens.
To examine whether the antibodies SWA 1, SWA21 and SWA22 recognise the same epitope, competition radioimmunoassays were performed (Table II) . Unlabelled SWA 11 at saturating concentration reduced the binding of radiolabelled SWA 11 to 10.9% whereas SWA21 and SWA22 reduced binding to 11.1 and 23.0% respectively. Antibody SWA20, which recognised a different small cell carcinoma antigen, did not compete with SWAl 1.
In vitro immunoreactivity
The lodogen radiolabelling reagent was employed routinely to produce iodinated SWAl1 with a specific activity in the range of 0.5-1.0 mCi mg-1. The biological activity of the labelled antibody was generally 65-70%, as shown in Figure 1 ( human buffy coat respectively and the respective association constants, K8, are 1.2 x109, 6.8x.108 and 3.6x108M-1.
In vivo localisation SWAl 1 antibody showed strong selective tumour localisation following i.v. injection into nude mice bearing SCC xenografts. Tissue to blood ratios of SWAl1 and control anti-CEA at days 2, 3, 4 and 7 are presented graphically in Figure 3a and b. Whereas no selective localisation of anti-CEA was observed, the tumour to blood ratios for SWAl1 were 2.4:1, 5.3:1, 7.5:1 and 8.0:1 at days 2, 3, 4 and 7 respectively. At day 4 the level of tumour accumulated SWAl 1 was 19, 22 and 12 times higher than levels in liver, kidney and spleen respectively.
The absolute levels of SWAl1 in tumour and various organs (as %ID g-1) are presented in Table III . SWAI1 displays a high localisation at day 2 with 10.5%IDg-1 of tumour. The antibody remains bound to the tumour maintaining 8%ID g-1 on days 3 and 4 and then falling to 4.8%IDg-1 by day 7.
Gamma scintigraphy
The selective accumulation of SWAl1 in SW2 xenografts at 2 and 4 days following injection was confirmed by external gamma scintigraphy, as displayed in Figure 4a and b respectively. On day 2 the tumour was already clearly visible against the background of activity still present in the blood pool in the visceral organs of the thorax. By day 4 the background level was markedly reduced, whereas the tumour remained relatively constant in terms of image intensity. The unblocked thyroid was visible at this time due to accumulation and relative retention of free 1311.
Discussion
We present in this paper a new monoclonal antibody of murine origin directed against an SCC-associated antigen. The strong competition described here between SWAl1 and SWA21 and 22 and a comparison of their patterns of tissue reactivity suggest that SWAI1 should also be grouped as cluster w4 as defined at the International Workshop on SCC, London, 1987. The antigen defined by SWAl1 is strongly expressed on the SW2 cell line, with around 6.1 x 105 antigenic binding sites per cell. The association constant was determined to be 1.2 x 109 M-1, a relatively high value and a good indicator of the high potential of SWAI 1 as a localising agent (Mach et al., 1981) .
By comparison with other anti-SCC antibodies described in the literature the SWAl 1 seems to be the most promising for utilisation in clinical imaging studies and for the delivery of therapeutically effective amounts of radioisotopes (radio- Ki, kidney; Sp, spleen; Lu, lung; He, heart; Th, thyroid; Fe, femur; Mu, muscle; Br, brain. --", , --. . Stya et al., 1987) . Studies on the IgM anti-SCC antibody MAb(600D 1) indicated tumour localisation of 3%ID g-1 at day 7 after injection but with poor tumour to normal tissue ratios (Zimmer et al., 1985) . The MAb 8 anti-SCC antibody has been shown to display unusual kinetics in that tumour accumulation progressed gradually throughout the study up to day 7, when a level of 7.4%IDg-1 was reached. However, the tumour to blood ratio at this point was only 2.7:1 and ratios for tumour to lung, kidney and liver were 5, 11 and 9:1 respectively (Endo et al., 1987) . Our studies on SWAl1 have shown localisation to tumour of 10.4%IDg-1 at day 2, around 8% at days 3 and 4 and 4.8% at day 7. Tumour to blood levels at the corresponding times were markedly better than those reported for other antibodies at 2.4, 5.3, 7.5 and 8:1. A representative sample of tumour to organ antibody levels at day 4 shows similarly high ratios at 19, 22, 12 and 44:1 for liver, kidney, spleen and muscle respectively.
The treatment of small cell cancer of the lung by RIT may prove particularly appropriate in view of the high radiosensitivity of the classic phenotype of the disease. SCC is highly invasive, often presenting in a widely disseminated form (De Leij et al., 1987; Stahel et al., 1985a) , and despite the very high initial sensitivity of the disease to chemotherapy it is prone to the rapid emergence of resistance to this form of attack. Such disseminated tumours have already been suggested as promising cases for the application of RIT (Dykes et al., 1987) . The emergent refractory form of the disease presumably originates from residual viable cells following first treatment and such residual cells may be more susceptible to the use of conventional chemotherapeutic protocols in conjunction with RIT as a combined modality. RIT has shown variable success in the treatment of human tumour xenografts grown in rodent models. In one study complete ablation of a radiosensitive neuroblastoma has been reported (Cheung et al., 1986) but other reports show a high dependency on the age of the tumour, with only limited inhibition of growth in those which are well established (Epenetos, 1984; Badger et al., 1986; Sharkey et al., 1987) . In view of the high localising capacity of SWAl1, its persistence at the tumour, its accompanying low blood and normal tissue levels and the inherent radiosensitivity of SCC we are now encouraged to examine the efficacy of SWAl1 as a radioimmunotherapeutic agent in our xenograft model system.
